“GLP-1 analogues are reshaping diabetes and obesity care as innovation in drug delivery, expanding indications, and strong R&D pipelines drive explosive global demand.” Boston, Jan. 30, 2026 (GLOBE ...
MedPage Today on MSN
New Kink in the Link Between GLP-1 Drugs and Cognition
By extending survival, GLP-1 agents may expand the dementia risk period for diabetes patie ...
For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently so ...
GLP-1 drugs like Wegovy alone do not work, may benefit more from a combination treatment, a recent review of the evidence ...
MetaVia begins patient dosing in Part 3 of phase 1 study of DA-1726, a GLP-1 and glucagon dual agonist to treat obesity: Cambridge, Massachusetts Monday, April 13, 2026, 11:00 Hrs ...
The Drugs Consultative Committee (DCC), during its 68th meeting, deliberated on strengthening regulatory oversight and ...
Researchers map the peptide behind semaglutide across 25 brain regions in each sex, finding striking differences in appetite and reward circuits. GLP-1 analogs, used to treat obesity, are among the ...
Oklahoma researchers found the hormone FGF21 targets the same brain region as GLP-1 drugs, but works by boosting metabolic ...
The Chosun Ilbo on MSN
GLP-1 in joints suggests direct arthritis treatment pathway
A research team from Aarhus University in Denmark has confirmed for the first time that the hormone GLP-1, used in obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results